ACME UNITED CORP - 10-Q Summary (Q1 1996)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1996. ACME United Corporation operates through U.S. Consumer and Medical divisions, as well as international subsidiaries in Germany, England, and Canada. The company is currently undergoing restructuring, including the sale of its German subsidiary, Peter Altenbach and Son GmbH, and the consolidation of U.S. manufacturing facilities.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Net Sales | $12,040,000 | $12,897,000 |
| Gross Margin | 24.4% | 28.1% |
| Net Loss | $(816,000) | $(68,000) |
| Loss Per Share | $(0.24) | $(0.02) |
| Cash and Equivalents | $352,000 | $661,000 |
| Net Cash Used in Operations | $(851,000) | $(539,000) |
| Total Debt (Current + Long Term) | $19,152,000 | Not explicitly stated (Derived from prior period data) |
| Working Capital | $16,062,000 | $15,976,000 |
| Current Ratio | 2.51 | 2.42 |
Material Changes vs. Prior Period
- Sales Decline: Net sales decreased 7% year-over-year. The German subsidiaries contributed a 21% decline, and the U.S. Medical Division dropped 14% due to hospital consolidation and reimbursement policy changes.
- Margin Compression: Gross margin fell from 28.1% to 24.4%, attributed to excess manufacturing capacity across all locations except Canada.
- Increased Loss: Net loss widened significantly from $68,000 to $816,000, driven by lower sales and reduced margins.
- Inventory Reduction: The company successfully reduced inventory levels, generating $310,000 in cash flow from operations, though this was offset by a decrease in accounts payable.
Outlook, Risks, and Unusual Items
- Asset Sale: On May 1, 1996, the company sold the assets of its Altenbach subsidiary for $960,000. An estimated loss of $1.6M to $1.9M is expected, but management states this will not significantly impact earnings as exit costs were accrued in 1995.
- Restructuring: Consolidation of Bridgeport, CT, and Fremont, NC facilities is underway to address excess capacity, expected to complete by the end of Q2 1996.
- Liquidity: The company maintains a $13M revolving line of credit with approximately $10.87M available. Management plans to fund debt reduction and operations through inventory liquidation and cash flow.
- Risks: Continued pressure on the U.S. Medical Division from market consolidation and competition; reliance on seasonal school product markets for U.S. debt fluctuations.
Investor Verification Checklist
- Verify the actual cash proceeds and final loss calculation from the Altenbach subsidiary sale upon closing.
- Monitor the timeline and cost savings associated with the consolidation of the Bridgeport and Fremont facilities.
- Assess the effectiveness of new pricing structures and market research in reversing the U.S. Medical Division's sales decline.
- Review the utilization of the $13M revolving credit line and the company's ability to reduce debt as planned.
- Confirm the status of the German subsidiary Emil Schlemper's deferred orders and their impact on Q2 revenue.